

## FIRST LIGHT

### RESEARCH

#### BOB ECONOMICS RESEARCH | FPI FLOWS

How have FPIs performed this year?

#### BOB ECONOMICS RESEARCH | FINANCIAL SAVINGS

Bank Deposits or Mutual Funds?

#### CUMMINS INDIA | TARGET: Rs 1,600 | +1% | HOLD

Robust quarter; positives in the price

#### SYRMA SGS | TARGET: Rs 400 | +51% | BUY

Strong topline but margins soften

### SUMMARY

#### INDIA ECONOMICS: FPI FLOWS

FPI flows into India has largely remained negative this year mirroring a trend seen across EM countries. A wide of range factors such as the Russia-Ukraine war, higher global rates, strengthening dollar, China factor as well dimming global growth prospects kept investors risk averse. In India, FPI flows did witness bouts of revival but the momentum has once again derailed amidst a domestic stock market rout, further exacerbated by Fed's unyielding fight against inflation and reopening in China. FPI flows are important to India as these help to supplement the funding requirements caused by a growing current account deficit. With India's CAD expected to widen to ~3% of GDP in FY23, FDI and ECB inflows may not be enough to fund the deficit. FPIs have remained volatile for much of this year with increasing risk and hence they may not contribute positively to our balance of payments.

[Click here for the full report.](#)

#### INDIA ECONOMICS: FINANCIAL SAVINGS

The present financial year has been quite unusual in the sense that consumption kept ticking even with inflation being high as the pent up demand phenomenon played out. Savings were affected for sure and this was manifested in slower growth in deposits to begin with. How about mutual funds, which tend to compete with banks when it comes to savings allocation? In the foregoing analysis we look at the movement in bank deposits and AUM of mutual funds for the period April 2022 and December 2022.

[Click here for the full report.](#)

**BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda**

Important disclosures and analyst certifications are provided at the end of the report.

#### Daily macro indicators

Indicator	07-Feb	08-Feb	Chg (%)
US 10Y yield (%)	3.67	3.61	(6bps)
India 10Y yield (%)	7.31	7.34	3bps
USD/INR	82.70	82.49	0.3
Brent Crude (US\$/bbl)	83.7	85.1	1.7
Dow	34,157	33,949	(0.6)
Hang Seng	21,299	21,284	(0.1)
Sensex	60,286	60,664	0.6
India FII (US\$ mn)	06-Feb	07-Feb	Chg (\$ mn)
FII-D	(48.3)	(99.6)	(51.3)
FII-E	(126.0)	(266.9)	(140.9)

Source: Bank of Baroda Economics Research

**BOBCAPS Research**  
 research@bobcaps.in



**CUMMINS INDIA**

- Q3 strong with revenue up 25% YoY despite supply chain constraints, as infrastructure-led demand improved; exports grew 23%
- Generator business guided to deliver sustainable long-term growth post absorption of CPCB4-related price hikes
- We raise FY23-FY25 EPS 4-12% and reset to a 35x P/E (vs. 30x) for a new TP of Rs 1,600 (vs. Rs 1,300); retain HOLD as positives priced in

[Click here](#) for the full report.

**SYRMA SGS**

- Q3 topline growth robust at 70% YoY led by resilient domestic demand; order book expands further to Rs 21bn
- EBITDA margin down 300bps YoY to 9.3% on higher RM cost and weakness in exports & healthcare business
- We revise FY23/FY24 EPS by +7%/-3%; on rollover, our TP moves to Rs 400 (from Rs 390) – retain BUY

[Click here](#) for the full report.

## FPI FLOWS

09 February 2023

## How have FPIs performed this year?


FPI flows into India has largely remained negative this year mirroring a trend seen across EM countries. A wide of range factors such as the Russia-Ukraine war, higher global rates, strengthening dollar, China factor as well dimming global growth prospects kept investors risk averse. In India, FPI flows did witness bouts of revival but the momentum has once again derailed amidst a domestic stock market rout, further exacerbated by Fed's unyielding fight against inflation and reopening in China. FPI flows are important to India as these help to supplement the funding requirements caused by a growing current account deficit. With India's CAD expected to widen to ~3% of GDP in FY23, FDI and ECB inflows may not be enough to fund the deficit. FPIs have remained volatile for much of this year with increasing risk and hence they may not contribute positively to our balance of payments.

**Aditi Gupta**  
Economist

## FPI movement in FYTD23

FPI flows have always been unpredictable and this year too was not an exception. While there was considerable volatility in the movement in FPI flows, overall the year saw total FPI outflows of US\$ 5.7bn. This is on top of outflows of US\$ 16bn in FY22. The trend in FPI flows this year has largely been negative, with the first three months of FY23 witnessing outflows of US\$ 14.3bn. Some of these losses were recovered in Q2FY23 with inflows of US\$ 6.9bn and US\$ 4.9bn in Q3FY23. However, the situation has quickly reversed since then with Jan'23 witnessing outflows of US\$ 3.2bn. It must be noted that the equity flows have dominated the overall trend in FPI flows as these account for the bulk of FPI inflows. FPI movement in debt and debt related instruments has remained largely muted this year.

Figure 1: FPI flows in FYTD23



Source: NSDL, Bank of Baroda Research, Data as of 6 Feb 2023 | Note: Others include Debt-VRR and Hybrid

## FPI movement over the years

In the last 5 years (FY18 to FY22), total FPI flows have remained negative for 3 years with the exception of FY18 and FY21. Both these years saw sizeable FPI inflows of more than US\$ 20bn, which more than offset the outflows seen in the other years. Interestingly, debt inflows of US\$ 18.5bn accounted for the bulk of FPI inflows in FY18 (inflows of US\$ 22.5bn). However, in FY21, which saw inflows of US\$ 36.2bn, equity segment saw huge FPI inflow of US\$ 37bn.



## FINANCIAL SAVINGS

09 February 2023

### Bank Deposits or Mutual Funds?

The present financial year has been quite unusual in the sense that consumption kept ticking even with inflation being high as the pent up demand phenomenon played out. Savings were affected for sure and this was manifested in slower growth in deposits to begin with. How about mutual funds, which tend to compete with banks when it comes to savings allocation? In the foregoing analysis we look at the movement in bank deposits and AUM of mutual funds for the period April 2022 and December 2022.

**Dipanwita Mazumdar**  
Economist

It is important to note that as RBI kept hiking the repo rate there was a tendency for bank deposits to also increase to match the increasing demand for credit. Notably, higher deposit rates have garnered an increase in deposits in the last few months. MFs on the other hand have been impacted by downside risks to global growth and tighter financial conditions, which impacted market fundamentals. Increase in Sensex (point to point) has also been considerably lower at 3.3% in FYTD'23 (last close: 06 Feb 2023) compared to 18.3% increase seen in FY22.

Thus, overall AUM of MFs have risen by only Rs 2.3 lakh crore and if the same momentum is maintained it will not be able to reach Rs 6.1 lakh crore accretion seen in FY22. Equity still holds up in FYTD23 compared to debt segment. The rising interest rate cycle has acted as a deterrent due to the discounting factor involved in pricing. The degree of substitutability between MF and bank deposits which in FY22 was slightly tilting towards MF, is showing reversal with Bank deposits being the preferred choice of allocation.

#### What has been the situation in FYTD23?

- In the first 9 months of FY23 (Apr-Dec), AUMs of MFs have increased to Rs 39.9 lakh crore in Dec'22 from Rs 37.6 lakh crore seen in Mar'22. This is an accretion of Rs 2.3 lakh crore. During this same period, Bank deposits have increased by Rs 12.7 lakh crore.
- Within MFs, equity funds have shown the maximum increase from Rs 13.7 lakh crore to Rs 15.3 lakh crore, an accretion of Rs 1.6 lakh crore. This is line with 3.3% increase in Sensex during the same period. Allocation in small cap and multi cap funds rose the most.
- Hybrid funds which invest 65 to 100% in equity also showed slight increase in the first 9 months of FY23. From Rs 4.8 lakh crore, it rose to Rs 4.9 lakh crore. This is led by Dynamic Asset Allocation/Balanced Advantage Fund, where investment in equity/debt that is managed dynamically and Multi Asset Allocation Fund.
- Debt funds on the other hand, have been a disappointment. The inflow in this segment moderated to 12.7 lakh crore in Dec'22 from Rs 13.5 lakh crore in Mar'22, thus showing decline of Rs 0.9 lakh crore. This is led by fall in allocation towards Banking and PSU Fund and other short duration funds.



**HOLD**  
 TP: Rs 1,600 | ▲ 1%

**CUMMINS INDIA**

| Capital Goods

| 09 February 2023

**Robust quarter; positives in the price**

- Q3 strong with revenue up 25% YoY despite supply chain constraints, as infrastructure-led demand improved; exports grew 23%
- Generator business guided to deliver sustainable long-term growth post absorption of CPCB4-related price hikes
- We raise FY23-FY25 EPS 4-12% and reset to a 35x P/E (vs. 30x) for a new TP of Rs 1,600 (vs. Rs 1,300); retain HOLD as positives priced in

Vinod Chari | Tanay Rasal  
 Nilesh Patil  
 research@bobcaps.in

**Strong Q3:** Despite supply chain constraints, KKC achieved revenue growth of 25% YoY in Q3FY23 to Rs 21.9bn (Rs 21.1bn est.), thanks to robust demand in both domestic and export markets which grew by 27% and 23% YoY respectively. The infrastructure segment, which had been lagging, showed significant improvement, and exports continued to hold up. The company’s EBITDA margin remained robust at 18.9%, up 330bps YoY, due to healthy pricing power. This translated into higher net profits of Rs 4.1bn (Rs 2.8bn est.), up 66% YoY.

**Exports a bright spot:** Despite past management commentary on potential headwinds, exports have held up well, rising 23% YoY (+2% QoQ) to Rs 5.4bn in Q3. Notably, sales to Europe – an area where management had previously expressed a cautious outlook – improved by 39% QoQ to reach Rs 970mn.

**Positive long-term outlook:** KKC expects the implementation of CPCB4 norms in July’23 to drive price hikes of 30-50% on its power generation equipment. While these steep hikes could cause a temporary demand blip for one or two quarters, the company expects to return to a sustainable growth trajectory (at twice the pace of GDP) for the next 2-3 years underpinned by demand from data centres, infrastructure, real estate and hospitality. We note that KKC has recently launched fuel-agnostic engines which addresses a key concern for the power-gen business.

**Supply chain still constrained:** Supply chain troubles continue to plague the company, marked by shortages of key electronics and components. Management indicated that any uptick in demand from China could further aggravate the situation.

**Retain HOLD:** Given guidance of sustained long-term growth in the domestic market and with exports holding strong, we raise FY23/FY24/FY25 EPS estimates by 12%/4%/4% and hike our target P/E multiple to 35x from 30x – a 30% premium to the 5Y average. Upon rolling valuations forward to Dec’24E, we reset to a higher TP of Rs 1,600 (vs. Rs 1,300). However, we retain our HOLD rating as the stock has run up 14% over the past 2 months, pricing in the positives and capping upside potential at just 1%.

**Key changes**



Ticker/Price	KKC IN/Rs 1,578
Market cap	US\$ 5.3bn
Free float	49%
3M ADV	US\$ 11.6mn
52wk high/low	Rs 1,618/Rs 909
Promoter/FPI/DII	51%/10%/25%


Source: NSE | Price as of 9 Feb 2023

**Key financials**

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	61,709	72,950	81,549
EBITDA (Rs mn)	8,681	11,408	11,611
Adj. net profit (Rs mn)	7,814	10,690	11,347
Adj. EPS (Rs)	28.2	38.6	40.9
Consensus EPS (Rs)	28.2	34.5	40.7
Adj. ROAE (%)	16.0	19.9	19.3
Adj. P/E (x)	56.0	40.9	38.6
EV/EBITDA (x)	51.9	40.1	39.6
Adj. EPS growth (%)	25.5	36.8	6.1

Source: Company, Bloomberg, BOBCAPS Research

**Stock performance**



Source: NSE



**BUY**  
 TP: Rs 400 | ▲ 51%

**SYRMA SGS**

Consumer Durables

09 February 2023

**Strong topline but margins soften**

- Q3 topline growth robust at 70% YoY led by resilient domestic demand; order book expands further to Rs 21bn
- EBITDA margin down 300bps YoY to 9.3% on higher RM cost and weakness in exports & healthcare business
- We revise FY23/FY24 EPS by +7%/-3%; on rollover, our TP moves to Rs 400 (from Rs 390) – retain BUY

Nilesh Patil | Vinod Chari  
 Tanay Rasal  
 research@bobcaps.in

**Q3 ahead of estimates:** Syrma beat our Q3FY23 estimates as resilient domestic demand more than compensated for weakness in exports. The topline increased 70% YoY to Rs 5.1bn (Rs 4.1bn est.) as the auto/consumer electricals & appliances segments continued to witness strong traction, growing 70%/3x YoY. This offset a 76% YoY contraction in the healthcare segment amidst inflationary pressures in overseas markets, especially Europe. A stronger topline coupled with higher other income aided Q3 net profit of Rs 332mn (Rs 233mn est.), up 68% YoY.

**Margins moderate:** A doubling of raw material cost YoY dragged the gross margin down to 25.4% (-890bps YoY, -400bps QoQ). Additionally, the margin-accretive industrials and healthcare segments delivered slower growth than the low-margin auto and durables businesses. EBITDA margin thus moderated 300bps YoY (-80bps QoQ) to 9.3% vs. 9.8% expected. Net working capital days inched up marginally to 83 days on a sequential basis.

**Strong order book; guidance maintained:** As of Dec'22, Syrma had outstanding orders worth Rs 21bn (vs. Rs 17bn in Q2FY23), with fresh intake of ~Rs 9bn from the industrial, consumer and auto verticals. Management continues to guide for revenue growth in line with the industry over the next couple of years and aims to achieve lower-double-digit margins on a sustainable basis. Exports (currently 35-40% of business) are guided to remained muted for the next two quarters but should be compensated for by domestic demand, thereby minimising the topline impact.

**Maintain BUY:** We believe Syrma has multiple growth levers in the form of a strong order book, timely capacity addition and traction in the auto, industrial and consumer verticals. Exports and working capital management are, however, key areas to watch in the near term. We adjust our FY23/FY24 EPS estimates by +7%/-3% to incorporate the Q3FY23 print as well as the shift in product mix. On rolling valuations forward to Dec'24, our TP increases to Rs 400 (earlier Rs 390), based on an unchanged 35x P/E multiple, a 15% discount to our EMS coverage comprising DIXON and AMBER. Maintain BUY.

**Key changes**

Target	Rating
▲	◀ ▶

Ticker/Price	SYRMA IN/Rs 265
Market cap	US\$ 566.7mn
Free float	53%
3M ADV	US\$ 1.6mn
52wk high/low	Rs 343/Rs 248
Promoter/FPI/DII	47%/5%/8%


Source: NSE | Price as of 9 Feb 2023

**Key financials**

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	12,666	18,945	25,319
EBITDA (Rs mn)	1,260	1,783	2,502
Adj. net profit (Rs mn)	765	1,170	1,606
Adj. EPS (Rs)	4.3	6.6	9.1
Consensus EPS (Rs)	4.3	-	-
Adj. ROAE (%)	13.8	11.0	9.9
Adj. P/E (x)	61.2	40.0	29.1
EV/EBITDA (x)	37.1	26.2	18.7
Adj. EPS growth (%)	16.7	53.0	37.3

Source: Company, Bloomberg, BOBCAPS Research

**Stock performance**



Source: NSE



**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

## Disclaimer

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom ("UK"):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.